Annual Meeting

Using bacteria to clean the environment

Núria  Negrão
April 28, 2021

In recent years, concerns have heightened about increasing amounts of drugs in the environment, particularly in water. While the impact of this environmental pollution is not well understood, some evidence indicates that these drugs may be entering the food chain. Researchers  believe that most of the drugs that end up in fresh water first accumulate at wastewater treatment facilities. Therefore, there is a need to eliminate the drugs at these facilities.

Ashley Robinson, a senior biochemistry major at Hamline University who plans to start graduate school in the fall, started doing research in her sophomore year. She is presenting a poster at the 2021 ASBMB Annual Meeting on this topic, the third research project she has worked on with Betsy Martínez–Vaz.

Kathryn Malody
Ashley Robinson works in the biological safety hood at the Martínez–Vaz lab.

The researchers’ goal was to find bacteria that break down metformin, a drug commonly used to treat diabetes in the U.S. and around the world. Little research has been done on the impact of pollution with metformin and its byproduct, guanylurea, which are not fully metabolized by humans and thus are excreted into wastewater systems. “We consider them to be emerging pollutants,” Robinson said.

Ashley Robinson & James Aukema
This graphic represents the topics of Robinson’s research. With increasing prescription of the Type 2 diabetes drug metformin (top), both metformin and its predominant metabolite, guanylurea (bottom), are water pollutants of emerging concern worldwide. The researchers recently isolated a strain of Pseudomonas that can completely degrade guanylurea from a wastewater treatment facility (middle). They identified and characterized a guanylurea-degrading enzyme, guanylurea hydrolase.

Studies have demonstrated the potential for metformin to disrupt some hormones, she explained. The drug  is considered an endocrine disruption agent in some small fishes, and guanylurea has been shown to interfere with the nitrogen cycle in soil. Little is known about its bioaccumulation potential.

“Can these molecules pass up the food chain?” Robinson said. “That is one concern that we have.”

The research team collected samples at a local wastewater treatment facility from several stages of the treatment process. The bacteria in the samples were then grown in the lab under limiting conditions, meaning the bacteria were not given all the nutrients they needed. In this case, their only source of nitrogen was metformin, so most of the bacteria that survived were species that could use metformin as a nitrogen source. The team then used metagenomics to identify the enzymes involved in the breakdown of guanylurea and its transformation product guanidine. They identified three enzymes: guanylurea hydrolase, carboxyguanidine deiminase and allophanate hydrolase.

Robinson and her colleagues are now working to identify the enzyme that breaks down metformin in the initial step that forms guanylurea. They hope the enzymes they find could be used to break down metformin and guanylurea at wastewater treatment facilities, keeping these pollutants out of freshwater systems.


Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Núria  Negrão

Núria Negrão is a medical writer and editor at Cactus Communications.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

How sugars shape Marfan syndrome
Journal News

How sugars shape Marfan syndrome

Sept. 10, 2025

Research from the University of Georgia shows that Marfan syndrome–associated fibrillin-1 mutations disrupt O glycosylation, revealing unexpected changes that may alter the protein's function in the extracellular matrix.

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.